Zacks Investment Research Downgrades Natera (NTRA) to Sell

Natera (NASDAQ:NTRA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

Several other equities analysts have also weighed in on the company. Morgan Stanley reissued an “overweight” rating and set a $16.00 price objective (up from $13.00) on shares of Natera in a report on Friday, October 6th. Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 price target on shares of Natera in a report on Tuesday, November 14th. Cowen reaffirmed a “buy” rating and issued a $12.00 price target on shares of Natera in a report on Thursday, December 21st. Robert W. Baird reaffirmed a “buy” rating on shares of Natera in a report on Tuesday, October 24th. Finally, BidaskClub raised Natera from a “strong sell” rating to a “sell” rating in a report on Saturday. Three analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $14.50.

Natera (NASDAQ:NTRA) opened at $11.54 on Tuesday. Natera has a twelve month low of $7.35 and a twelve month high of $14.76. The firm has a market capitalization of $597.37, a price-to-earnings ratio of -4.71 and a beta of 2.07. The company has a current ratio of 1.85, a quick ratio of 1.75 and a debt-to-equity ratio of 2.43.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. The firm had revenue of $56.66 million for the quarter, compared to the consensus estimate of $55.31 million. During the same period last year, the company posted ($0.50) earnings per share. Natera’s revenue for the quarter was up 5.1% on a year-over-year basis. equities research analysts predict that Natera will post -2.15 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Virtu KCG Holdings LLC purchased a new stake in shares of Natera in the second quarter worth $126,000. Russell Investments Group Ltd. purchased a new stake in shares of Natera in the third quarter worth $171,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Natera during the second quarter valued at about $151,000. Voya Investment Management LLC raised its position in Natera by 17.8% during the second quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 2,212 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in Natera by 2.8% during the second quarter. Wells Fargo & Company MN now owns 18,031 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 491 shares in the last quarter. 66.23% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Downgrades Natera (NTRA) to Sell” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/01/23/zacks-investment-research-downgrades-natera-ntra-to-sell.html.

Natera Company Profile

Natera, Inc is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply